Abstract 6015: Unveiling RYK: A breakthrough tumor-associated antigen in lymphoma treatment
Matilde Micillo(Department of Medical Sciences), Silvia Deaglio(Department of Medical Sciences), Tiziana Vaisitti(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Marta Coscia(University of Turin), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Katti Jessen(Intel (United States)), Brian J. Lannutti(Fate Therapeutics (United States)), Victor Navarro‐Tableros(CSI Piemonte), Giulia Omezzolli(Department of Medical Sciences), Francesco Edoardo Vallone(Department of Medical Sciences), Amelia Fascì(Department of Medical Sciences), Beatrice Pirajno(Department of Medical Sciences), Nahal Nabelsi(Department of Medical Sciences), Elisabetta Bolli(Department of Public Health), Samir Mouhissine(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Candida Vitale(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino)
Cited by 0
Related Papers
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
|The Journal of Experimental Medicine|2007|2.4k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The translational landscape of mTOR signalling steers cancer initiation and metastasis
|Nature|2012|1.4k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890